1-7 of 7
Carla Grandori
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Shogo Shigeta, Goldie Y.L. Lui, Reid Shaw, Russell Moser, Kay E. Gurley, Grace Durenberger, Rachele Rosati, Robert L. Diaz, Tan A. Ince, Elizabeth M. Swisher, Carla Grandori, Christopher J. Kemp
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (4): 691–703.
https://doi.org/10.1158/1535-7163.MCT-20-0809
Published: 01 April 2021
View article titled, Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Open the PDF for Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract A28: Casein kinase 1ε (CSNK1ε) is a synthetic lethal target in MYC-driven ovarian cancer

Goldie Y. L. Lui, Franz Schaub, Shaifali Agrawal, Kazuyuki Kitatani, Christopher J. Kemp, Masafumi Toyoshima, Carla Grandori
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (10_Supplement): A28.
https://doi.org/10.1158/1538-8514.SYNTHLETH-A28
Published: 02 October 2017
View article titled, Abstract A28: Casein kinase 1ε (CSNK1ε) is a synthetic lethal target in MYC-driven ovarian cancer
Journal Articles

Abstract PR05: Construction of synthetic lethal networks for p53 tumor suppressor pathways identifies candidate therapeutic targets for metastatic, chemotherapy resistant HNSCC

Russell Moser, Chang Xu, Michael Kao, In Sock Jang, Kay Gurley, Adam Margolin, Carla Grandori, Eddie Mendez, Chris Kemp
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): PR05.
https://doi.org/10.1158/1535-7163.PMS-PR05
Published: 01 May 2014
View article titled, Abstract PR05: Construction of synthetic lethal networks for p53 tumor suppressor pathways identifies candidate therapeutic targets for metastatic, chemotherapy resistant HNSCC
Journal Articles

Abstract A37: Cross-cancer evaluation of MYC synthetic lethal targets in The Cancer Genome Atlas

Brady Bernard, Silvia Cermelli, Carla Grandori, Ilya Shmulevich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): A37.
https://doi.org/10.1158/1535-7163.PMS-A37
Published: 01 May 2014
View article titled, Abstract A37: Cross-cancer evaluation of MYC synthetic lethal targets in The Cancer Genome Atlas
Journal Articles

Abstract IA11: Identification of therapeutic targets for MYC-driven cancers by functional genomics

Masafumi Toyoshima, In Sock Jang, Silvia Cermelli, Brady Bernard, Carla Grandori
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): IA11.
https://doi.org/10.1158/1535-7163.PMS-IA11
Published: 01 May 2014
View article titled, Abstract IA11: Identification of therapeutic targets for MYC-driven cancers by functional genomics
Journal Articles

Abstract C135: Therapeutic targets for MYC-driven cancer.

Masafumi Toyoshima, Heather Howie, Maki Imakura, Ryan Walsh, Julie Park, Carla Grandori
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C135.
https://doi.org/10.1158/1535-7163.TARG-11-C135
Published: 12 November 2011
View article titled, Abstract C135: Therapeutic targets for MYC-driven cancer.
Journal Articles

Abstract A65: MicroRNA miR‐210 modulates cellular response to hypoxia through the MYC antagonist MNT

Hong Sun, Zhan Zhang, Carla Grandori
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A65.
https://doi.org/10.1158/1535-7163.TARG-09-A65
Published: 10 December 2009
View article titled, Abstract A65: MicroRNA miR‐210 modulates cellular response to hypoxia through the MYC antagonist MNT